ELI ANDERSON: Open Payments
NPI 1053342634 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,129 in 47 payments from 10 companies in 2025. Trend: 2023 $1,345 · 2024 $913 · 2025 $1,129
Food & beverage: $1,129
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $283 |
| ABBVIE INC. | 7 | $249 |
| Neurocrine BioSciences, Inc. | 7 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $163 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Alkermes, Inc. | 3 | $70 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $13 |
Products named: UZEDY, VRAYLAR, INGREZZA, CAPLYTA, ARISTADA, COBENFY, INVEGA SUSTENNA, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
